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Pharmacokinetic/pharmacodynamic analyses with Monte Carlo Simulations (MCS) can be 
used to integrate prior information on model parameters to a new renal replacement therapy 
(RRT) to develop optimal drug dosing when pharmacokinetic trials are not feasible. This 
study utilized MCS to determine initial doripenem, imipenem, meropenem, and ertapenem 
dosing regimens for critically ill patients receiving prolonged intermittent RRT (PIRRT). 
Published body weights and pharmacokinetic parameter estimates (non-renal clearance, free 
fraction, volume of distribution, extraction coefficients) with variability were used to develop 
pharmacokinetic model. MCS of 5,000 patients evaluated  multiple regimens in 4 different 
PIRRT effluent/duration combinations (4 L/hour x 10 hours or 5 L/hour x 8 hours in 
hemodialysis or hemofiltration) occurring at the beginning or 14-16 hours after drug infusion. 
Probability of target attainment (PTA) was calculated using ≥ 40% free serum concentrations 
above 4 times the MIC for the first 48 hours. Optimal doses were defined as the smallest 
daily dose achieving ≥90% PTA in all PIRRT combinations. At the MIC of 2mg/L for 
Pseudomonas aeruginosa, optimal doses were doripenem 750 mg q8h, imipenem 1 g q8h or 
750 mg q6h, and meropenem 1 g q12h or 1 g pre- and post-PIRRT. Ertapenem 500 mg 
followed by 500 mg post-PIRRT was optimal at the MIC of 1mg/L for Streptococcus 
pneumoniae. Incorporating data from critically ill patients receiving RRT into MCS resulted 
in markedly different carbapenem dosing regimens in PIRRT from those recommended for 
conventional RRTs due to the unique drug clearance characteristics of PIRRT. These results 
warrant clinical validation. 
 
 
Keywords: doripenem, ertapenem, imipenem, meropenem, pharmacokinetics, prolonged 
















Sepsis is a primary cause of acute kidney injury requiring renal replacement therapy 
(RRT) in critically ill patients. Septic acute kidney injury is associated with higher mortality 
than non-septic acute kidney injury (70% vs. 52%),
1
 representing a profound healthcare 
burden. Along with supportive care, early antibiotic therapy that promptly achieves 
therapeutic concentrations at the infection site is paramount to cure the infection and to 
maximize patient survival.
2
  However, our knowledge deficit of antibiotic pharmacokinetics 
in critically ill patients receiving RRT poses a profound obstacle in determining optimal 
empiric dosing regimens. Many different types of RRTs have been employed to treat acute 
kidney injury in the ICU, but pharmacokinetic studies for many RRTs are unavailable, 
leading to use of widely varying antibiotic dosing regimens.
3
 Particularly, prolonged 
intermittent renal replacement therapy (PIRRT) is gaining interest as studies show similar 
patient outcomes to conventional RRT with better hemodynamic tolerance, improved patient 
mobility, and lower RRT operation cost.
4-8
 However, pharmacokinetic studies in PIRRT are 




 it is not feasible to conduct 
pharmacokinetic studies in critically ill patients receiving every type of RRT. Alternatively, 
in silico analyses using Monte Carlo Simulations (MCS) can be highly valuable to simulate 
the real world patient population and to predict efficacy/safety of drug dosing regimens. This 
approach maximizes the utility of existing antibiotic data and our current understanding of 




Carbapenems are β-lactam antibiotics with broad antibacterial activity against most 
Gram-positive and Gram-negative aerobes and anaerobes. With the emergence of multidrug-









 Carbapenems exhibit time-dependent bactericidal activity, and the 
pharmacodynamic parameter predicting outcomes is the percent of time during a dosing 
interval that free serum concentrations exceed the minimum inhibitory concentration 
(fT>MIC) for the infecting pathogen.
15
 Near-maximal bactericidal activity for carbapenems is 
achieved when fT>MIC is ≥ 40% of the dosing interval. However, it may be prudent to 
achieve free concentrations in excess of the MIC (e.g., 4xMIC) in critically ill patients to 
maximize bacterial killing and suppress bacterial resistance.
16
 Clinicians must consider the 
altered pharmacokinetics from acute illness and extracorporeal clearance when determining 
optimal carbapenem dosing regimens in critically ill patients receiving PIRRT. 
In the present study, we performed “in silico” pharmacokinetic and pharmacodynamic 
analyses for doripenem, imipenem, meropenem, and ertapenem consisting of 1) development 
of mathematical pharmacokinetic models with relevant demographic and pharmacokinetic 
data from published studies and four daily PIRRT settings, 2) performance of MCS for 
multiple dosing regimens in a virtual cohort, and 3) determination of probability of target 
attainment (PTA) for each regimen over a range of MICs. The objective of the study was to 
predict empiric carbapenem dosing regimens that are most likely to attain the pre-defined 
pharmacodynamic target to treat serious infections in critically ill patients receiving daily 
PIRRT using MCS.  
Subjects & Methods 
Development of Mathematical Pharmacokinetic Models  
The input parameters used in the analyses are outlined in Table 1.  Body weights and 
pharmacokinetic parameters were obtained from a published PIRRT study
 17 
and carbapenem 
pharmacokinetic studies in critically ill patients receiving RRT,
18-33
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patient population most likely to receive PIRRT. Calculating transmembrane drug clearance 
in RRT requires two important parameters – effluent flow rate (dialysate flow rate or/and 
ultrafiltration flow rate) and a measure of how well the drug crosses the hemodiafilter 
membrane (generically known as extraction coefficient; specifically sieving coefficient for 
hemofiltration and saturation coefficient for hemodialysis). The model incorporated four 
commonly employed PIRRT settings with two different effluent flow rate/duration 
combinations in two different RRT modalities.
7,17  
They were; 1) hemofiltration with 
ultrafiltrate flow rate of 4 L/hour for 10 hours/day, 2) hemofiltration with ultrafiltrate flow 
rate of 5 L/hour for 8 hours/day, 3) hemodialysis  with dialysate flow rate of 4 L/hour for 10 
hours/day, and 4) hemodialysis with dialysate flow rate of 5 L/hour for 8 hours/day. Blood 
flow rate was 300 mL/min in all PIRRT settings.
 
For hemofiltration, all replacement solutions 
were modeled to be infused in the pre-dilution mode as in clinical practice.  Extraction 
coefficients estimate the concentration of drug in ultrafiltrate or dialysate in relation to 
plasma and approximate unbound fraction of drug in plasma. Extraction coefficients for 
meropenem and imipenem in PIRRT were calculated from published reports using 
transmembrane clearance and effluent rates. Regression analyses were performed using 
previously reported transmembrane clearance at various ultrafiltrate or dialysate flow rates in 
RRT studies as variables.
19-28,34-44 
The best fitting relationships were modeled to extrapolate 
transmembrane clearance at the desired PIRRT ultrafiltrate or dialysate flow rate and to 
determine sieving or saturation coefficient respectively. The variability of extraction 
coefficient expressed as standard deviation was assumed to be 20% of the mean value.  This 
was extracted from the previous RRT studies, which generally expressed  ~20% variability in 
the unbound fraction data of carbapenems in critically ill patients with RRT.
18,20,22,23,28, 34-36,38-
39 
 Because ertapenem and doripenem had far less available critical care pharmacokinetic and 
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excerpted directly from the few clinical trials that were available.
29,30,32  
The equations used in 
the model were following:  
CLHD (L/hr) = SA * Qd 
CLHF (L/hr) = SC * Quf   * [Qplasma  / (Qplasma  + Qreplacement)]
45,46 
V (L) = WT * V (L/kg)  
kon = (CLNR + CLHD) / V            (for hemodialysis)  
kon = (CLNR + CLHF) / V             (for hemofiltration) 
koff = CLNR / V  
where CLHF is transmembrane clearance in hemofiltration, SC is sieving coefficient, 
Quf is ultrafiltrate flow rate, Qplasma is plasma flow rate [Qplasma = Qblood*(1- hematocrit);  
hematocrit is 30%
46
], Qreplacement is replacement fluid flow rate [Qreplacement = Quf],  CLHD is 
transmembrane clearance in hemodialysis, SA is saturation coefficient, Qd is dialysate flow 
rate, V is volume of distribution, WT (kg) is body weight,  kon is the elimination rate constant 
during PIRRT, CLNR is non-renal clearance, and koff  is the elimination rate constant off 
PIRRT.  
Monte Carlo Simulations (MCS) 
Pharmacodynamic exposures were modeled for 6-11 unique dosing regimens for each 
carbapenem.  They included those recommended for patients receiving other forms of RRT 
and those accounting for potentially different drug clearances during or off daily PIRRT (e.g. 
pre- and post-PIRRT regimens). Infusion times were 0.5 hour (ertapenem, imipenem ≤500 
mg, and meropenem) or 1 hour (doripenem, and imipenem >500mg).
47-50
 The initial 48 hours 
of free serum concentration-time profiles were simulated for each carbapenem dosing 
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above. One compartmental model with constant intravenous input and first-order elimination 
was used:    
fC(t) = [(f x Dose/T)/(k x Vd)] x (1 – e
–k x t
)                    (during the infusion) 




       (after the infusion) 
Where f is the fraction of unbound drug, C(t) is the carbapenem concentration at a 
specific time, T is infusion time, k is the elimination rate constant, Vd is volume of 
distribution, and t=the time from the infusion initiation.  
MCS (Crystal Ball Classroom Edition, Oracle) were performed to generate free serum 
concentration-time profiles of 5,000 virtual subjects in 1-hour intervals for each carbapenem 
regimen. Demographic and pharmacokinetic values were randomly selected from log-
Gaussian distributions within assigned limits.  The only exception was the ertapenem free 
fraction, which was randomly selected from a uniform distribution as reported in a previous 
study with critically ill patients.
33
 To prevent spurious simulations, reasonable limits were set 
for all parameters based on known ranges, as previously described.
51
 Body weights <40 kg 
were truncated because of the assumption was that study patients were adults. For volume of 
distribution and non-renal clearance, minimum and maximum values reported from all 
previously published studies were used as the lower and upper limits, respectively. For free 
fraction and sieving/saturation coefficient, values were assumed to be between 0 and 1. The 
correlation (i.e. coefficient of determination, r
2
) between body weight vs. volume of 
distribution or non-renal clearance was also integrated into the models to construct a virtual 
cohort with realistic pharmacokinetic parameters if available from the previous studies with 
RRT. The relationship found between these parameters appeared to be insignificant (Table 1).    
Our objective was to develop optimal empiric dosing recommendations in a wide 
variety of clinical situations. Carbapenems can be administered at the beginning of, or during 




This article is protected by copyright. All rights reserved. 
10 
 
dosing in all situations, we simulated each carbapenem dosing infused in the two extreme 
scenarios in each of four PIRRT settings. One scenario is when the first carbapenem dose is 
given at the beginning of PIRRT (early PIRRT), and the other is when infused 14 hours or 16 
hours prior to PIRRT (late PIRRT).  Dosing regimens were simulated for 48 hours to include 
two daily PIRRT sessions. 
 Prediction of Probability of Target Attainment (PTA) 
PTA was calculated for each dosing regimen using the pharmacodynamic target of ≥ 
40% fT>4xMIC for the first 48 hours at doubling MIC dilutions ranging from 0.125-32 mg/L. 
Briefly, fT>4xMIC, as a percentage of the dosing interval, was calculated for each of the 
5,000 virtual patients at a given MIC. PTA was calculated by summation of the number of 
patients achieving ≥ 40% fT>4xMIC and dividing by the total number of patients. Reference 
organisms used in the in silico analyses were Pseudomonas aeruginosa for doripenem, 
imipenem and meropenem, and Streptococcus pneumoniae for ertapenem. These organisms 
were chosen because they are associated with substantial morbidity and mortality in the ICUs 
and are common indications for carbapenem use.
52,53
 The susceptibility breakpoint for 
doripenem, imipenem and meropenem against P. aeruginosa is 2 mg/L and for ertapenem 
against S. pneumoniae is 1 mg/L.
54
 Thus, we evaluated attainment of  ≥ 40% fT>8 mg/L for 
doripenem, imipenem, and meropenem against P. aeruginosa and attainment of  ≥ 40% fT>4 
mg/L for ertapenem against S. pneumoniae. Optimal dosing regimens were selected if they 
provided  ≥ 90% PTA regardless of when PIRRT was given relative to the first antibiotic 
dose. However, benefits of achieving the pharmacodynamic target should be weighed against 
the risk of drug toxicity. No data exist to define carbapenem exposure and toxicity 
concentration threshold yet. However, carbapenem toxicity has been well documented with 
higher carbapenem doses (4 g/day) or in patients with severe renal insufficiency.
55,56
 Thus, 
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dose to minimize the risk of toxicity. Additionally, sensitivity analyses were performed to 
investigate the influence of different PIRRT regimens on carbapenem dosing in PIRRT. 
Since effluent flow rate is considered the most important covariate to determine 
extracorporeal drug clearance in RRT, PTA of the recommended carbapenem dosing 
regimens from this present study was re-evaluated in a wide array of effluent flow rates 
ranging from 2 to 8L/hr.  Sensitivity analyses were performed for all recommended doses in 8 
hour treatments in the hemodialysis and hemofiltration modes with early PIRRT. 
Results 
Table 2 summarizes the PTA of selected dosing regimens and the mean fT>4xMIC 
for the initial 48 hours at an MIC of 2 mg/L for doripenem, imipenem, and meropenem and 1 
mg/L for ertapenem. Differences in PTA in early or late PIRRT settings with the four 
different combinations of modalities and effluent rates were all within 1-2% of each other. 
For example, imipenem 1 g q8h yielded PTA of 97-98% in both early and late PIRRT 
settings in the four different PIRRT modalities. Thus, we present the results of the 8-hour 
hemodialysis PIRRT as a representative example of all regimens. Optimal initial dosing 
regimens using the smallest daily doses were meropenem 1 g q12h or 1 g pre- and post-
PIRRT, imipenem 1 g q8h or 750 mg q6h, doripenem 750 mg q8h, and ertapenem 500 mg 
initially followed by 500 mg post-PIRRT. Most carbapenem doses recommended for other 
forms of RRT did not attain ≥ 90% PTA. Those regimens accounting for the increased drug 
clearance during PIRRT (e.g. pre- and post-PIRRT regimens) did not result in better PTA 
than standard schedule dosing regimens. Figure 1 illustrates the PTA at 40% fT>4xMIC for 
select dosing regimens at specific MICs in 8-hour PIRRT which occurred either at the 
beginning (early PIRRT) or 16 hours after (late PIRRT) carbapenem therapy was initiated. 
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exposures at lower MIC values. The additional information on PTA of various carbapenem 
dosing regimens in the other three PIRRT settings is provided in the supplementary material.   
Table 3 displays mean model-derived drug clearances and half-lives for each 
carbapenem during and off an 8-hour PIRRT compared to published clinical data from 
continuous RRT (CRRT) and extended daily dialysis, another type of PIRRT. Overall 
carbapenem clearance by PIRRT was higher than that seen with CRRT, but similar to those 
by extended daily dialysis regimens. Consequently, carbapenem half-lives during PIRRT 
were shorter than those during CRRT, but were resulted in similar ranges as extended daily 
dialysis.    
Results of the sensitivity analyses are depicted in Table 4. PTA of the recommended 
carbapenem dosing regimens from the present study was not different in simulated 8 hour 
hemodialysis and hemofiltration PIRRT with various effluent flow rates.     
Discussion 
This is the first in silico study using MCS to determine optimal carbapenem dosing 
regimens in critically ill patients receiving daily PIRRT. This in silico approach has been 
used in previous studies to predict optimal drug dosing in special patient populations with 
limited pharmacokinetic data.
51,57,58
 Some of these studies were followed by pharmacokinetic 
validation trials.
58,59
 The dosing recommendations from these validation trials were in 
agreement with those predicted in the previous in silico studies,
58,59
 demonstrating that the in 
silico approach can be useful to guide drug dosing practice when extensive clinical trials 
cannot be conducted. In this present study, MCS allowed us to create a large number 
(n=5,000/tested dose) of virtual critically ill patients with acute kidney injury based on the 
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disposition. Pharmacokinetic/ pharmacodynamic analyses determined the carbapenem dosing 
regimens with the highest likelihood to attain the pre-defined pharmacodynamic target (40% 
fT>4xMIC in ≥ 90% of virtual patients) while minimizing toxicity risk in these virtual 
patients with PIRRT. 
The key component of this study is the relevance of input parameter estimates with 
associated variability. The demographic data were extracted from a published PIRRT study
17
 
and pharmacokinetic data from studies in critically ill patients with acute kidney injury 
receiving RRT,
18-33
 which are much different from pharmacokinetics in patients with chronic 
kidney disease receiving RRT.
60
 We also incorporated free fraction and non-renal clearance 
parameters from critically ill patients into the model. Lack of consideration for these 
important parameters has been identified as a limitation of previous clinical trials because 
assumption of free fraction and non-renal clearance can confound PTA estimation.
61,62
 Our 
pharmacokinetic models integrated four different, commonly-used, PIRRT operating 
parameters, including different RRT modalities (convection and dialysis), and RRT treatment 
durations (5 L/hour for 8 hours and 4 L/hour for 10 hours).  We modeled ultrafiltrate fluid 
replacement in the pre-dilution mode in hemofiltration and corrected hemofiltration PIRRT 
drug clearance accordingly,
45,46
 because administration of pre-filter hemofiltration 
replacement solutions decreases drug clearance by reducing hemofiltration efficiency. In 
general, drug clearance is higher in hemofiltration compared to hemodialysis. However, with 
correction for pre-dilution mode, carbapenem clearance in hemofiltration PIRRT approached 
that in hemodialysis PIRRT in all cases. Additionally, dosing regimens achieving optimal 
pharmacodynamic exposures for the 8-hour PIRRT session also achieved optimal exposures 
for the 10-hour PIRRT session. The increased time of RRT treatment offset differences in 
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For drug dosing in hybrid-type RRTs like PIRRT, “when” to give a drug in relation to 
RRT may be more important than “how much” drug to give.
63
 Our results demonstrate this 
premise is especially true for drugs with longer half-lives given infrequently (e.g., q12h-24h) 
but not for drugs given more frequently (q6h-8h) if the pharmacodynamic target is fT>MIC. 
For example, meropenem 500 mg q12h and ertapenem 500 mg q24h yielded significantly 
different PTA depending on when antibiotic therapy was initiated relative to the time of 
PIRRT (0.56 and 0.65 in early PIRRT vs. 0.63 and 0.97 in late PIRRT, respectively) (Table 
2). Sensitivity analysis suggests that to “when” give a drug in relation to RRT is also more 
important than what the effluent rate is during PIRRT.  Table 4 demonstrates that varying 
PIRRT intensity from 2L/hr up to 8L/hr while the duration of PIRRT is kept the same makes 
strikingly little difference in PTA.  Recommended doses that achieved acceptable PTA at the 
PIRRT regimens tested also met acceptable PTA even when effluent rates ran as high as 
8L/hr.  Only meropenem PTA dropped below 90% when faster effluent rates were modelled.  
Obviously at slower effluent rates (<4L/hr), PTA >90% would continue to be reached at the 
recommended doses, but lower doses should probably be used to avoid carbapenem toxicity. 
We evaluated whether the dosing strategy utilizing increased drug clearance during 
PIRRT (e.g. pre- and/or post-PIRRT regimens) can facilitate pharmacodynamic target 
attainment, as suggested in another simulation study with gentamicin in patients receiving 
extended daily dialysis or intermittent hemodialysis.
64
 We simulated meropenem 1g pre- and 
post-PIRRT to compare PTA with those using a standard schedule (q12h). However, pre- and 
post-PIRRT regimens did not result in better PTA than those with the standard schedule 
(Table 2) likely because of the different pharmacodynamic profiles of carbapenems versus 
gentamicin.  
Because of the paucity of pharmacokinetic data, clinicians may base carbapenem 
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receiving CRRT (Table 5).
65
 Our analysis suggests this is an undesirable approach. CRRT 
flow rates and treatment durations differ substantially from PIRRT. Further, recommended 
CRRT carbapenem doses in critically ill patients receiving CRRT often yield subtherapeutic 
concentrations and do not achieve optimal PTA.
61
 Therefore, clinicians should not directly 
compare published CRRT dosing regimens to our PIRRT findings to determine their 
appropriateness. In the present study, carbapenem removal by PIRRT was greater than those 
by CRRT resulting in shorter half-lives than those reported during CRRT, illustrated in Table 
3. Consequently, with the exception of ertapenem CRRT dosing recommendations, many 
carbapenem dosing regimens currently prescribed for CRRT did not achieve optimal 
pharmacodynamic exposures (Table 2). This is because PIRRT utilizes higher flow rates (4-5 
L/hour) than conventional CRRT (1-3 L/hour),
66,67
 yielding faster dialytic drug clearance 
(Table 3). In scenarios where the drug is infused with the initiation of 8-hour hemodialysis 
PIRRT, 60-90% of an infused dose (78%, 89%, 71%, and 62% on average for meropenem, 
imipenem, doripenem, and ertapenem, respectively) was removed during PIRRT, leading to 
subtherapeutic concentrations. This effect is less pronounced in CRRT which runs at slower 
effluent rates. As we attempted to identify optimal dosing regimens for all scenarios in 
relation to PIRRT, higher carbapenem doses were necessary to meet the pharmacodynamic 
target (≥ 40% fT>4xMIC).        
Among carbapenems, meropenem is most studied in terms of pharmacokinetic data 
and provides confidence in the pharmacokinetic parameters and robustness of the 
pharmacokinetic models. Our meropenem dosing recommendation of 2g/day (1 g q12h or 1g 
pre- and post-PIRRT) agrees with those suggested in published studies in other types of 
PIRRT including 8-hour extended daily dialysis (0.5-1 g q8h) or sustained low efficiency 
dialysis(1 g q12h)] (Table 5).
40,68
 These studies utilized higher effluent flow rates (160 
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lives (3.6-3.7 hours vs. 4.9 hours in our study).  However, authors of these trials used less 
rigorous efficacy criteria consequently their dosing recommendations were very similar to 
ours. In the present study, meropenem 1 g administered pre- and post-PIRRT achieved 
optimal pharmacodynamic exposures, but 1 g q12h was chosen for convenience.  
Imipenem and doripenem have not been studied in any hybrid-type RRT setting. Our 
model-derived dosing recommendations for PIRRT are higher than those recommended for 
CRRT (Table 5).
26,30,36,37  
Imipenem differs from the other carbapenems due to its uniquely 
elevated non-renal clearance reported in critically ill patients with acute kidney injury.
26,28,36
 
Doripenem displays the highest extracorporeal drug clearance due to its highest free fraction 
(≥ 90%). Based on our simulations, optimal empiric doses achieving ≥ 90% PTA were 2400 
mg/day and 1800 mg/day for imipenem and doripenem, respectively. However, 1 g q8h and 
750 mg q8h were selected for practical reasons. Currently recommended CRRT dosing 
regimens did not achieve optimal exposures when modeled in PIRRT.    
In contrast to other carbapenems, the optimal ertapenem dosing regimen in PIRRT 
required a similar dose (1g q24h) as those recommended for CRRT (0.5-1 g q24h) 
32
 or for 
patients receiving 8-hour extended daily dialysis with higher flow rates (effluent rate =160 
ml/min vs. =66~83 ml/min in present study) (Table 5). 
69
 This extended daily dialysis study 
did not evaluate different dosing strategies with respect to ertapenem administration timing 
relative to RRT to find the optimal dosing regimen. With high protein binding and slower 
non-renal clearance, ertapenem has a longer half-life than other carbapenems allowing for a 
smaller dose to achieve optimal exposures if administered after the PIRRT session ends. 
However, the first dose should be immediately administered regardless of PIRRT schedule to 
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This study has some important limitations. Pharmacokinetic modeling and simulations 
were performed assuming the patients were adult-sized with acute kidney injury and 
negligible renal drug clearance who received daily PIRRT. We constructed virtual patients 
using demographic and pharmacokinetic data from the literature. Thus, our recommended 
dosing regimens would be applicable only to patients who match these demographic and 
clinical characteristics. Because optimal empiric dosing regimens were chosen based on 
achieving ≥ 90% PTA, up to 10% of patients may not achieve the pharmacodynamic target 
using our recommended doses. We chose an aggressive pharmacodynamic target associated 
with maximal bacterial killing and suppression of bacterial resistance,
15,16
 and this aggressive 
target often resulted in the need for higher doses to achieve optimal exposures compared to 
doses utilized in contemporary practice. However, these doses are based on empiric coverage 
of P. aeruginosa for meropenem, imipenem, and doripenem (MIC 2 mg/L) and S. 
pneumoniae for ertapenem (1 mg/L). After culture and susceptibility results are known, 
dosing regimens may be adjusted depending on the sensitivity of the isolated pathogen. In 
addition, the recommended dosing regimens provide optimal exposures for susceptible 
Enterobacteriaceae because the susceptibility breakpoints for these organisms are lower than 
those evaluated in this study. The benefit of higher antibiotic doses should be balanced with 
the potential risk of drug toxicity in these vulnerable patients.
60
 Carbapenems are associated 
with CNS toxicity in the presence of renal disease,
55,56
 and patients should be monitored 
closely when employing these dosing regimens. 
Conclusions 
The use of an in silico approach to develop optimal carbapenem dosing in patients 
receiving PIRRT resulted in aggressive dosing recommendations that met PTA in 90% of 
virtual patients. Previous studies have shown that carbapenems are cleared by RRT and our 
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currently prescribed carbapenem dosing regimens
3
 for patients receiving hybrid-type RRTs 
would result in subtherapeutic concentrations. Meropenem 1 g q12h, imipenem 1 g q8h, 
doripenem 750 mg q8h, and ertapenem 500 mg initially followed by 500 mg post-PIRRT are 
recommended empirically to achieve optimal pharmacodynamic exposures in critically ill 
patients receiving daily 8 to 10 hour PIRRT.  
It is unlikely that pharmacokinetic trials for all these antibiotics at varying doses will 
ever be conducted using all the various ways that PIRRT can be run.  Further, in most 
countries, including our own, clinical assays are unavailable to determine whether therapeutic 
targets are attained with any dosing regimen. Consequently, this in silico approach provides 
rational clinical decision support for clinicians treating infected patients receiving PIRRT and 
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Table 1. Demographic and Pharmacokinetic Parameters Utilized in Monte Carlo Simulations 
Carbapenem Meropenem Imipenem Doripenem Ertapenem 
Weight  
(kg) 
86.6 ± 29.2 
[≥ 40] 
86.6 ± 29.2 
[≥ 40] 
86.6 ± 29.2 
[≥ 40] 
86.6 ± 29.2 
[≥ 40] 
Volume of Distribution 
(L/kg) 
0.41 ± 0.18 
[0.08-1.07] 
0.34 ± 0.1 
[0.21-0.63] 
0.47 ± 0.15 
[0.2-1.2] 




54.9 ± 49 
[0-251] 
100.5 ± 28 
[53-160] 
51 ± 45 
[0-231] 
11 ± 3 
[10-19] 
Free Fraction 0.79 ± 0.09 
[0-1] 
0.8 ± 0.16 
[0-1] 




Sieving Coefficient 0.84 ± 0.17 
[0-1] 
1 ± 0.2 
[0-1] 
0.65 ± 0.13 
[0-1] 
0.2 ± 0.06 
[0-1] 
Saturation Coefficient 0.6 ± 0.12 
[0-1] 
0.5 ± 0.1 
[0-1] 
0.65 ± 0.13 
[0-1] 
0.2 ± 0.06 
[0-1] 
Correlation between 






0.17 N/A 0.3318 
 
Correlation between 
Weight vs. Non-renal 
0.0072 
 










All values are mean ± SD [assigned model limits]. 
Data obtained from references 17-44. 
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Table 2. Probability of Target Attainment (%) of Selected Carbapenem Dosing Regimens in 
8-Hour Hemodialysis-based PIRRT Using a 5 L/hour Dialysate Flow Rate.   
Carbapenem Dosing Early PIRRT Late PIRRT 








(mean ± SD) 
Meropenem 500mg q12h 56 46 ± 25 63 52 ± 29 
 1g q12h 89 75 ± 22 92 81 ± 23 
 11.6mg/kg q12h 87 74 ± 24 90 80 ± 24 
  500mg q8h 84 69 ± 24 84 72 ± 27 
 1g q8h 97 88 ± 17 97 91 ± 17 
 1g pre & post PIRRT 90 79 ± 24 89 78 ± 25 
Imipenem 500mg q12h 1 17 ± 10 4 21 ± 12 
 500mg q8h 35 35 ± 17 35 35 ± 17 
 750mg q8h 85 59 ± 18 87 61 ± 19 
 1g q8h 98 73 ± 17 98 75 ± 18 
 500mg q6h 72 53 ± 20 77 56 ± 21 
 750mg q6h 98 79 ± 16 99 81 ± 16 
Doripenem 250mg q12h 7 9 ± 16 12 14 ± 19 
 500mg q12h 58 47 ± 26 68 56 ± 29 
 250mg q8h 36 29 ± 28 36 30 ± 29 
 500mg q8h 86 71 ± 23 87 75 ± 25 
 750mg q8h 97 86 ± 15 97 89 ± 17 
Ertapenem 500mg q24h 65 50 ± 20 97 75 ± 14 
 750mg q24h 94 77 ± 21 99 90 ± 09 
 1g q24h 98 90 ± 16 100 95 ± 7 
 500mg initially, then 
500mg post PIRRT  
99 91 ± 8 98 80 ± 15 
a
 MIC = 2 mg/L for meropenem, imipenem, and doripenem (susceptibility breakpoint for 
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%fT>4xMIC denotes the percent of time in the first 48 hours of therapy that the free fraction 
was four times greater that the target MIC for that drug. 
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Table 3. Carbapenem Clearances and Half-Lives in PIRRT in Comparison to Published Data 
in CRRT and EDD   
Present Study in PIRRT Meropenem Imipenem Doripenem Ertapenem 
CLon-PIRRT  (L/hr) 5.9 ± 2.5 8.5 ± 1.5 6.1 ± 2.3 1.7 ± 0.3 
CLoff-PIRRT  (L/hr) 3.1 ± 2.4 5.9 ± 1.4 2.9 ± 2.2 0.7 ± 0.1 
CLPIRRT (L/hr) 2.8 ± 0.5 2.6 ± 0.5 3.2 ± 0.6 1.0 ± 0.3 
t½ on-PIRRT (hr) 4.9 ± 3.4 2.7 ± 1.4 5.2 ± 3.1 7.5 ± 3.9 
t½ off-PIRRT (hr) 14.2 ± 16.7 3.9 ± 2.2 16.5 ± 17.7 18.2 ± 9.6 









0.6 ± 0.24 
[32] 








CLEDD  (L/hr) 2.3 (0.7-3.7) 
[40] 
N/A N/A 2.97 ± 0.65 
[69] 
t½ EDD (hr) 3.7 (2.1-4.7) 
[40] 
N/A N/A 6.7 ± 0.4 
[69] 
CLon-PIRRT : total drug clearance during PIRRT, CLoff-PIRRT : total drug clearance off PIRRT,  
CLPIRRT : drug clearance by PIRRT, CLCRRT : drug clearance by CRRT, CLEDD : drug 
clearance during EDD, t½ :half-life, CRRT : continuous renal replacement therapy; EDD : 
extended daily dialysis; N/A : not available 
Numbers in brackets represent references. Numbers in parentheses represent data ranges.  
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Table 4. PTA Sensitivity Analyses of Recommended Carbapenem Dosing Recommendation 




8 hour Hemodialysis PIRRT 
Dialysate  










500mg post PIRRT 
2 90 99 97 99 
3 90 98 97 99 
4 89 98 97 99 
  5* 89 98 97 99 
6 88 98 97 99 
7 88 98 97 99 
8 87 98 96 99 
8 hour Hemofiltration PIRRT 
Ultrafiltration  










500mg post PIRRT 
2 91 99 97 99 
3 90 99 97 99 
4 89 98 97 99 
  5* 88 98 97 99 
6 88 98 97 99 
7 87 97 97 99 









 MIC = 2 mg/L for meropenem, imipenem, and doripenem (susceptibility breakpoint for 
Pseudomonas aeruginosa) and 1 mg/L for ertapenem (susceptibility breakpoint for 
Streptococcus pneumoniae). 
*Reference flow rate used in this study 
PTA data were from 8-Hour PIRRT using a 5 L/hour effluent flow rate (dialysate or 
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IHD 250mg-1g q24h with 






500mg q12h on Day 
1, then 500mg q24h 
[70] 
 
500mg q24h with 
150mg supplemental 
dose 6 hours  
prior to IHD 
[50] 










EDD/SLED 1g q12h or 
500mg-1g q8h 
[40,68] 




1g q12h 1g q8h 750mg q8h 500mg initially, then 
500mg post-PIRRT 
 
IHD: Intermittent Hemodialysis, CRRT: Continuous Renal Replacement Therapy, 
EDD/SLED: Extended Daily Dialysis / Sustained Low-Efficiency Dialysis, N/A: Not 
Available   
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Figure 1. Probability of Target Attainment in the First 48 Hours of Carbapenem Dosing Regimens at Different 
MICs 
 
Meropenem Early 8-Hour HD PIRRT                        Meropenem Late 8-Hour HD PIRRT 
 
Imipenem Early 8-Hour HD PIRRT                      Imipenem Late 8-Hour HD PIRRT 
 




























































































































































































































Ertapenem Early 8-Hour HD PIRRT                                  Ertapenem Late 8-Hour HD PIRRT 
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Early PIRRT is when the first carbapenem dose is administered at the start of an 8-hour 
hemodialysis PIRRT session with a 5L/hr dialysate flow rate. Late PIRRT is when the first 
carbapenem dose is administered 16 hours before a daily 8-hour hemodialysis PIRRT 
session. 
 
 
 
 
 
 
 
 
 
 
 
 
